Top 25 medical and healthcare startups in Sweden
Mar 18, 2026
|
Like
22
1
Funding: SEK213.5M
Oncorena is developing a new treatment for metastatic kidney cancer based on orellanine - toxin from the Cortinarius mushroom family that exhibits potent cytotoxic activity in kidney cells. The company's candidate, ONC175, is a synthetic orellanine that is administered intravenously and actively and selectively penetrates kidney cancer cells. Preclinical studies have shown that the drug targets kidneys and kidney-derived cancer cells through highly specific uptake. The molecular mechanism of uptake was identified as the presence of solute transporters expressed almost exclusively on kidney cancer cells and renal proximal tubule cells. The company is currently conducting clinical trials of the drug.
Oncorena is developing a new treatment for metastatic kidney cancer based on orellanine - toxin from the Cortinarius mushroom family that exhibits potent cytotoxic activity in kidney cells. The company's candidate, ONC175, is a synthetic orellanine that is administered intravenously and actively and selectively penetrates kidney cancer cells. Preclinical studies have shown that the drug targets kidneys and kidney-derived cancer cells through highly specific uptake. The molecular mechanism of uptake was identified as the presence of solute transporters expressed almost exclusively on kidney cancer cells and renal proximal tubule cells. The company is currently conducting clinical trials of the drug.
2
Funding: $33.6M
Elypta is developing MIRAM - metabolomics-based liquid biopsy test for the early detection of cancer. MIRAM utilizes state-of-the-art laboratory methods for the extraction and detection of glycosaminoglycans (GAGs), delivering high and reliable performance in a standardized and scalable manner. The method is based on enzymatic digestion, which depolymerizes GAGs into disaccharides. Measurements can be performed in a wide range of research samples, such as blood, urine, tissue, cell cultures, and other biological fluids. Relatively small sample volumes are required to obtain accurate results across the entire glycosaminoglycan profile. The company is conducting a series of clinical studies to evaluate the effectiveness of its liquid biopsy in various cancer types.
Elypta is developing MIRAM - metabolomics-based liquid biopsy test for the early detection of cancer. MIRAM utilizes state-of-the-art laboratory methods for the extraction and detection of glycosaminoglycans (GAGs), delivering high and reliable performance in a standardized and scalable manner. The method is based on enzymatic digestion, which depolymerizes GAGs into disaccharides. Measurements can be performed in a wide range of research samples, such as blood, urine, tissue, cell cultures, and other biological fluids. Relatively small sample volumes are required to obtain accurate results across the entire glycosaminoglycan profile. The company is conducting a series of clinical studies to evaluate the effectiveness of its liquid biopsy in various cancer types.
3
Funding: $729.4M
With KRY’s app, you can meet a doctor or therapist at any time or location, using your phone or tablet.
With KRY’s app, you can meet a doctor or therapist at any time or location, using your phone or tablet.
4
Funding: $325.1M
Neko has created a new AI-based medical scanning technology concept that allows for comprehensive and non-invasive health data collection that is both convenient and economical for the general people.
Neko has created a new AI-based medical scanning technology concept that allows for comprehensive and non-invasive health data collection that is both convenient and economical for the general people.
5
Funding: $210.4M
Calliditas Therapeutics, a specialty pharmaceutical company that develops pharmaceutical products in fields of unmet medical need. Its products include Nefecon, a treatment for IgA nephropathy and Busulipo, an alternative for myeloablation prior to bone marrow transplantation.
Calliditas Therapeutics, a specialty pharmaceutical company that develops pharmaceutical products in fields of unmet medical need. Its products include Nefecon, a treatment for IgA nephropathy and Busulipo, an alternative for myeloablation prior to bone marrow transplantation.
6
Funding: $189.9M
Doktor.se is a modern and personal care company working with digital healthcare.
Doktor.se is a modern and personal care company working with digital healthcare.
7
Funding: $87.6M
OxThera is developing its Oxabact therapy that uses the O. formigenes bacteria to degrade oxalates in the intestines.
OxThera is developing its Oxabact therapy that uses the O. formigenes bacteria to degrade oxalates in the intestines.
8
Funding: $71.6M
Doccla is a healthtech startup with a platform that can monitor patients on hospital wards and in the home
Doccla is a healthtech startup with a platform that can monitor patients on hospital wards and in the home
9
Funding: €36M
Asgard Therapeutics has developed a reprogramming technology to generate functional immune cell types capable of triggering immune responses. Its approach utilizes the concept of a "Trojan horse" (TrojanDC), which can be administered to different patients, triggering the presentation of tumor (neo)antigens and activating personalized antitumor responses. It targets tumor heterogeneity and bypasses tumor immune evasion. Asgard's lead program, AT-108, is pioneering the development of a ready-to-use, personalized treatment applicable to a wide range of oncological diseases.
Asgard Therapeutics has developed a reprogramming technology to generate functional immune cell types capable of triggering immune responses. Its approach utilizes the concept of a "Trojan horse" (TrojanDC), which can be administered to different patients, triggering the presentation of tumor (neo)antigens and activating personalized antitumor responses. It targets tumor heterogeneity and bypasses tumor immune evasion. Asgard's lead program, AT-108, is pioneering the development of a ready-to-use, personalized treatment applicable to a wide range of oncological diseases.
10
Funding: $33.2M
Joint Academy is a digital clinic that provides digital treatment for patients with osteoarthritis and chronic joint pain.
Joint Academy is a digital clinic that provides digital treatment for patients with osteoarthritis and chronic joint pain.
12
Funding: $28.2M
NuvoAir combines hardware, software and data to improve lives of people suffering from respiratory conditions
NuvoAir combines hardware, software and data to improve lives of people suffering from respiratory conditions
13
Funding: €50K
XVIVO Perfusion is a medical technology company. We are firmly rooted in medical science and our core business is in ex vivo organ preservation. We are focused on developing optimized solutions for organ, tissue and cell preservation and perfusion in connection with transplantation. We have more than 15 years of experience within the transplant industry and are dedicated to providing more effective, clinically proven and innovative products that both increase the availability of acceptable donor organs and improve survival after transplantation.
XVIVO Perfusion is a medical technology company. We are firmly rooted in medical science and our core business is in ex vivo organ preservation. We are focused on developing optimized solutions for organ, tissue and cell preservation and perfusion in connection with transplantation. We have more than 15 years of experience within the transplant industry and are dedicated to providing more effective, clinically proven and innovative products that both increase the availability of acceptable donor organs and improve survival after transplantation.
14
Funding: $21.7M
Lifesum is a Swedish digital health startup that helps clients become healthier by using applied psychology and technology.
Lifesum is a Swedish digital health startup that helps clients become healthier by using applied psychology and technology.
15
Funding: $15.8M
Acorai is a medical device manufacturer of non-invasive intracardiac pressure monitoring to improve heart failure management.
Acorai is a medical device manufacturer of non-invasive intracardiac pressure monitoring to improve heart failure management.
16
Funding: $12.6M
Flow is the next wave of mental health treatment, combining brain stimulation and behaviour therapy in a unique programme to treat Major Depressive Disorder.
Flow is the next wave of mental health treatment, combining brain stimulation and behaviour therapy in a unique programme to treat Major Depressive Disorder.
18
Funding: $9.5M
Alex Therapeutics provides the platform that enables our partners to effectively and reliably launch new digital therapeutics (DTx) by leveraging existing insights, modules, processes and data.
Alex Therapeutics provides the platform that enables our partners to effectively and reliably launch new digital therapeutics (DTx) by leveraging existing insights, modules, processes and data.
19
Funding: $3.6M
Engaging Care is focused on the development of treatment programs for chronic and lifestyle related diseases.
Engaging Care is focused on the development of treatment programs for chronic and lifestyle related diseases.
20
Funding: €3.3M
The goal for CombiGene is to develop gene therapy treatment methods that can improve the lives of milions of people all over the world.
The goal for CombiGene is to develop gene therapy treatment methods that can improve the lives of milions of people all over the world.
21
Funding: SEK15M
Geras Solutions aims to provide a clear pathway towards a reliable dementia specialist that is time and cost-effective. The Geras Solutions App offers individuals living with dementia and carers an ecosystem of digital dementia supportive solutions via an easy to use mobile health tool.
Geras Solutions aims to provide a clear pathway towards a reliable dementia specialist that is time and cost-effective. The Geras Solutions App offers individuals living with dementia and carers an ecosystem of digital dementia supportive solutions via an easy to use mobile health tool.
23
Funding: €71.4K
Double Bond Pharmaceutical has developed ways to treat these brain cancer, liver cancer and pneumonia much more effectively with its drug delivery system.
Double Bond Pharmaceutical has developed ways to treat these brain cancer, liver cancer and pneumonia much more effectively with its drug delivery system.
24
Thermaiscan is combining AI with thermal sensors in smartphones to solve the problem with late detection of breast cancer development. The innovation is enhancing non-specialist healthcare personnel with a breast cancer pre-screening solution. It is for the first line of healthcare that has the very first contact with patients in mini clinics, primary care units and in rural areas.
★
See also:
